|
Neurocrine Biosciences ، Inc. (NBIX) تقييم DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Neurocrine Biosciences, Inc. (NBIX) Bundle
وفر الوقت وتحسين الدقة مع حاسبة (NBIX) DCF! مع الوصول إلى بيانات العلوم البيولوجية العصبية الحقيقية والافتراضات القابلة للتخصيص ، تمكنك هذه الأداة من التنبؤ وتحليل وقيمة علوم الأحياء العصبية مثل المستثمر المخضرم.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,045.9 | 1,133.5 | 1,488.7 | 1,887.1 | 2,355.3 | 2,538.4 | 2,735.7 | 2,948.3 | 3,177.5 | 3,424.5 |
| Revenue Growth, % | 0 | 8.38 | 31.34 | 26.76 | 24.81 | 7.77 | 7.77 | 7.77 | 7.77 | 7.77 |
| EBITDA | 336.1 | 218.7 | 264.6 | 358.0 | 610.1 | 579.1 | 624.2 | 672.7 | 725.0 | 781.3 |
| EBITDA, % | 32.14 | 19.29 | 17.77 | 18.97 | 25.9 | 22.82 | 22.82 | 22.82 | 22.82 | 22.82 |
| Depreciation | 8.6 | 10.9 | 15.6 | 21.3 | 27.1 | 25.9 | 28.0 | 30.1 | 32.5 | 35.0 |
| Depreciation, % | 0.82226 | 0.96162 | 1.05 | 1.13 | 1.15 | 1.02 | 1.02 | 1.02 | 1.02 | 1.02 |
| EBIT | 327.5 | 207.8 | 249.0 | 336.7 | 583.0 | 553.2 | 596.2 | 642.5 | 692.5 | 746.3 |
| EBIT, % | 31.31 | 18.33 | 16.73 | 17.84 | 24.75 | 21.79 | 21.79 | 21.79 | 21.79 | 21.79 |
| Total Cash | 801.0 | 711.3 | 989.3 | 1,031.6 | 1,076.1 | 1,554.2 | 1,675.0 | 1,805.2 | 1,945.5 | 2,096.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 157.1 | 185.5 | 350.0 | 439.3 | 479.1 | 500.1 | 539.0 | 580.9 | 626.1 | 674.7 |
| Account Receivables, % | 15.02 | 16.37 | 23.51 | 23.28 | 20.34 | 19.7 | 19.7 | 19.7 | 19.7 | 19.7 |
| Inventories | 28.0 | 30.5 | 35.1 | 38.3 | 57.4 | 61.9 | 66.7 | 71.9 | 77.5 | 83.5 |
| Inventories, % | 2.68 | 2.69 | 2.36 | 2.03 | 2.44 | 2.44 | 2.44 | 2.44 | 2.44 | 2.44 |
| Accounts Payable | 39.4 | 51.5 | 67.3 | 108.9 | 110.0 | 118.1 | 127.3 | 137.2 | 147.9 | 159.4 |
| Accounts Payable, % | 3.77 | 4.54 | 4.52 | 5.77 | 4.67 | 4.65 | 4.65 | 4.65 | 4.65 | 4.65 |
| Capital Expenditure | -10.9 | -23.4 | -16.5 | -28.3 | -38.2 | -37.2 | -40.1 | -43.3 | -46.6 | -50.2 |
| Capital Expenditure, % | -1.04 | -2.06 | -1.11 | -1.5 | -1.62 | -1.47 | -1.47 | -1.47 | -1.47 | -1.47 |
| Tax Rate, % | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 | 29.77 |
| EBITAT | 1,250.1 | 183.6 | 179.9 | 253.2 | 409.4 | 449.2 | 484.1 | 521.7 | 562.3 | 606.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 1,102.1 | 152.3 | 25.7 | 195.3 | 340.5 | 420.5 | 437.4 | 471.4 | 508.1 | 547.6 |
| WACC, % | 5.55 | 5.53 | 5.51 | 5.51 | 5.51 | 5.52 | 5.52 | 5.52 | 5.52 | 5.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,020.8 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 569 | |||||||||
| Terminal Value | 37,385 | |||||||||
| Present Terminal Value | 28,573 | |||||||||
| Enterprise Value | 30,594 | |||||||||
| Net Debt | 222 | |||||||||
| Equity Value | 30,372 | |||||||||
| Diluted Shares Outstanding, MM | 104 | |||||||||
| Equity Value Per Share | 292.88 |
What You Will Get
- Real NBIX Financials: Access to historical and projected data for precise valuation.
- Adjustable Inputs: Tailor WACC, tax rates, revenue growth, and capital expenditures to your needs.
- Automatic Calculations: Dynamic computation of intrinsic value and NPV.
- Scenario Analysis: Evaluate multiple scenarios to assess Neurocrine’s future performance.
- Clear and Intuitive Design: Designed for professionals while remaining user-friendly for newcomers.
Key Features
- Real-Time NBIX Data: Pre-loaded with Neurocrine Biosciences' historical financials and future projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Neurocrine Biosciences data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Neurocrine Biosciences’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Neurocrine Biosciences, Inc. (NBIX)?
- User-Friendly Interface: Tailored for both novice and seasoned users.
- Customizable Inputs: Adjust assumptions easily to suit your analytical needs.
- Real-Time Updates: Monitor immediate changes in Neurocrine's valuation as you tweak inputs.
- Preloaded Data: Comes with Neurocrine’s actual financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Professionals: Understand the intricacies of drug development and market analysis for Neurocrine Biosciences (NBIX).
- Researchers: Utilize advanced models to incorporate Neurocrine's innovative therapies into studies and publications.
- Investors: Evaluate your investment strategies and assess the potential of Neurocrine Biosciences (NBIX) in the biotech sector.
- Market Analysts: Enhance your reports with a customizable framework for analyzing Neurocrine's financial performance.
- Pharmaceutical Entrepreneurs: Gain valuable insights into how established biotech companies like Neurocrine Biosciences (NBIX) navigate the market.
What the Template Contains
- Pre-Filled Data: Includes Neurocrine Biosciences' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Neurocrine Biosciences' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.